OMRONOMRON 6645 ↗

Caveat

For the year ended March 2026 (FY3/2026), reported 2026-05-13, consolidated net sales were JPY 767,351m (+7.3% YoY), operating income JPY 59,935m (+12.1%), and net income attributable to OMRON shareholders JPY 28,487m (+75.1%); ROE improved to 3.5% from 2.1% and ROIC to 3.0% from 1.8%. By segment, Industrial Automation (IAB), the P01/P16-relevant sensing, safety and control business that also houses Omron's AMR line, was JPY 409.5bn of revenue (+12.3%) and JPY 42.8bn of operating income (+18.0%), roughly 53% of group sales; Healthcare (HCB, blood-pressure monitors and other consumer medical devices) was JPY 145.3bn (-0.4%); Social Systems (SSB, energy/infrastructure) JPY 144.3bn (+0.5%); Data Solutions (DSB, the JMDC health-data platform) JPY 51.2bn (+19.7%).

The company attributes IAB's growth to 'expanding generative AI demand': semiconductor-domain revenue +20% YoY and secondary-battery-domain revenue +27% YoY, with X-ray inspection systems (AXI) revenue +140% on data-center and PCB/EMS demand, not to humanoid or general robotics demand; AMR revenue is not broken out separately. Q1 FY3/2027 (April-June 2026), reported 2026-08-05, showed the trend accelerating: consolidated revenue JPY 209,900m (+26.1%), operating profit JPY 18,900m (+226.0%), net profit JPY 10,600m (+131.1%); IAB revenue JPY 131,200m (+37.2%), operating profit JPY 21,300m (+100.8%).

Full-year guidance for the year ending March 2027 was raised the same day to revenue JPY 880.0bn (+14.6%), operating profit JPY 80.0bn (+41.7%), net profit JPY 40.5bn (+82.1%), again on semiconductor/data-center capex, with no AMR, cobot or humanoid demand cited anywhere in the release. The stock has re-rated roughly in line with this recovery: up about 68% over the trailing 52 weeks (JPY 3,690 to JPY 7,245) against a trailing P/E near 29x on TTM net income of JPY 34.5bn; TTM revenue is JPY 810.7bn, and the FY3/2027 dividend is planned at JPY 110/share, up JPY 6 from JPY 104.

IAB is roughly half of group revenue and the clear P01/P16 exposure, but the other half sits in blood-pressure monitors, energy/infrastructure systems and a health-data platform with no robotics relevance: a real but partial and diluted line into the site's sensing and safety bottlenecks, and not a name whose own disclosures point to humanoid demand.

风险提示

截至 2026 年 3 月的财年（FY3/2026，2026-05-13 公布）：合并净销售额 7,673.51 亿日元（同比 +7.3%），营业利润 599.35 亿日元（+12.1%），归属 Omron 股东净利润 284.87 亿日元（+75.1%）；ROE 从 2.1% 升至 3.5%，ROIC 从 1.8% 升至 3.0%。分事业部看：工业自动化事业部（IAB，对应 P01/P16 的传感、安全与控制业务，也是 Omron AMR 产品线所在部门）收入 4,095 亿日元（+12.3%），营业利润 428 亿日元（+18.0%），约占集团收入的 53%；医疗健康事业部（HCB，血压计等消费医疗器械）1,453 亿日元（-0.4%）；社会系统事业部（SSB，能源/基础设施）1,443 亿日元（+0.5%）；数据解决方案事业部（DSB，JMDC 健康数据平台）512 亿日元（+19.7%）。

公司将 IAB 增长归因于"生成式 AI 需求扩张"——半导体领域收入同比 +20%，二次电池领域收入 +27%，X 射线检测设备（AXI）收入因数据中心与 PCB/EMS 需求增长 +140%——并未将人形机器人或一般机器人需求列为驱动因素，AMR 收入也未单独披露。FY3/2027 第一季度（2026 年 4–6 月，2026-08-05 公布）显示趋势加速：合并收入 2,099 亿日元（+26.1%），营业利润 189 亿日元（+226.0%），净利润 106 亿日元（+131.1%）；IAB 收入 1,312 亿日元（+37.2%），营业利润 213 亿日元（+100.8%）。

同日上调截至 2027 年 3 月财年的全年指引：收入 8,800 亿日元（+14.6%），营业利润 800 亿日元（+41.7%），净利润 405 亿日元（+82.1%）——驱动因素仍是半导体/数据中心资本开支，公告中未提及 AMR、协作机器人或人形机器人需求。市场的重新定价大致与这一复苏同步：过去 52 周股价上涨约 68%（从 3,690 日元升至 7,245 日元），基于 TTM 净利润 345 亿日元的市盈率约 29 倍；TTM 收入 8,107 亿日元，FY3/2027 计划派息 110 日元/股，较上一年度的 104 日元增加 6 日元。

IAB 约占集团收入的一半，是明确对应 P01/P16 的敞口，但另一半是血压计、能源/基础设施系统与健康数据平台，与机器人无关——这是本站传感与安全类瓶颈中真实但被稀释的一条敞口，且公司自身披露并未指向人形需求。